An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
Conditions: Systemic Lupus Erythematosus; Systemic Sclerosis; Inflammatory Myopathy; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Sjogren ' s Syndrome Interventions: Other: YTS109 Sponsors: China Immunotech (Beijing) Biotechnology Co., Ltd.; Shanghai Changzheng Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
Conditions: Diffuse Cutaneous Systemic Sclerosis Interventions: Drug: Telitacicept; Drug: Mycophenolate Mofetil Sponsors: Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
Conditions: Systemic Lupus Erythematosus (SLE); Sjogren ' s Syndrome; Systemic Sclerosis; Inflammatory Myopathy; ANCA Associated Vasculitis; Antiphospholipid Syndrome Interventions: Biological: Anti-CD19-CD3E-CAR-T cells Sponsors: Shanghai Changzheng Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Evaluating Tools to Communicate Scleroderma Research Results to Patients
Conditions: Scleroderma; Systemic Sclerosis Interventions: Other: Plain-language summary; Other: Dissemination Tool (Infographic) Sponsors: Lady Davis Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus; Idiopathic Inflammatory Myopathies; Systemic Sclerosis; IgG4 Related Disease; Primary Sj ögren Syndrome Interventions: Biological: T cell injection targeting CD19 chimeric antigen receptor Sponsors: PersonGen BioTherapeutics (Suzhou) Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus; Lupus Nephritis; Autoimmune Diseases; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Granulomatous Polyangiitis; Microscopic Polyangiitis; Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Sjogren ' s Syndrome Interventions: Biological: CD19- BCMA CAR-T cells Sponsors: Essen Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Conditions: Systemic Lupus Erythematosus; Systemic Sclerosis; Dermatomyositis; Polymyositis Interventions: Drug: anti-CD19 CAR T cell therapy Sponsors: University of Erlangen-N ürnberg Medical School Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Rheumatology Diet Study
Conditions: Diet Habit; Rheumatologic Disease; Autoimmune Diseases; Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Dermatomyositis/Polymyositis; Sjogren ' s Syndrome; Systemic Lupus Erythematous; Scleroderma; Fibromyalgia Sponsors: University of Central Florida Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
Making it Work Program for Systemic Sclerosis
Conditions: Scleroderma, Systemic Interventions: Other: Making it Work Systemic Sclerosis Sponsors: University of New Mexico Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
Faecal Microbiota Transplantation Against Chronic Diarrhea in Patients With Systemic Sclerosis
Conditions: Diarrhea; Systemic Sclerosis Interventions: Procedure: Faecal Microbiota Transplantation (FMT); Procedure: Placebo Sponsors: University of Aarhus Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Conditions: Systemic Sclerosis; Scleroderma Interventions: Biological: CABA-201 Sponsors: Cabaletta Bio Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Conditions: Systemic Sclerosis; Scleroderma Interventions: Biological: CABA-201 Sponsors: Cabaletta Bio Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Idiopathic Inflammatory Myopathies; Systemic Sclerosis Interventions: Biological: CD19-CAR-DNT cells Sponsors: RenJi Hospital; Guangdong Ruishun Biotech Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
Conditions: Systemic Sclerosis; Interstitial Lung Disease Interventions: Drug: Tocilizumab; Drug: Nintedanib; Drug: Standard therapy Sponsors: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland; Medical Research Agency, Poland Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot
Conditions: Systemic Sclerosis; Raynaud Phenomenon Interventions: Device: Observation - Nailfold capillaroscopy Sponsors: University of Manchester; National Institute for Health Research, United Kingdom; Royal Bolton Hospital NHS Foundation Trust; Alder Hey Children ' s NHS Foundation Trust; University Hospitals of Morecambe Bay NHS Trust; Stockport NHS Foundation Trust; Medway NHS Foundation Trust; Northern Care Alliance NHS Foundation Trust; Royal Free Hospital NHS Foundation Trust Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
